Uney, KamilEr, AyseAvci, Gulcan ErbilBulbul, AzizElmas, MuammerYazar, Enver2020-03-262020-03-2620091680-5593https://hdl.handle.net/20.500.12395/23464The effect of tilmicosin on serum cytokine concentrations were investigated in healthy and lipopolysaccharide-treated mice. The mice were divided into 3 groups. Lipopolysaccharide (250 mu g, Escherichia coli 0111:B4, intraperitoneally) was injected into the positive control group. The other 2 groups received tilmicosin (20 mg kg(-1), subcutaneously) concurrently without or with lipopolysaccharide. After treatment, serum samples were collected at 0, 1.5, 3, 6, 12 and 24 h. Serum tumor necrosis factor, interleukin-1 and interleukin-10 levels were determined by enzyme-linked immunosorbent assay. Lipopolysaccharide increased all cytokine levels in the healthy mice. Tilmicosin slightly induced interleukin-1 production in the healthy mice, while it had no effect on tumor necrosis factor or interleukin-10 productions. However, tilmicosin elevated (p<0.05) tumor necrosis factor, interleukin-1 and interleukin-10 levels in lipopolysaccharide-treated mice. In conclusion, these data suggest that tilmicosin stimulates both proinflammatory and antiinflammatory cytokines at the dose recommended for infection.eninfo:eu-repo/semantics/closedAccessTilmicosinlipopolysaccharideTNFIL-1IL-10Article8510211024WOS:000265889000037N/A